EGCG attenuates METH self‐administration and reinstatement of METH seeking in mice

Abstract

AbstractMethamphetamine (METH) use disorder is a chronic, relapsing disorder and involves frequent failures of self‐control of drug seeking and taking. Epigallocatechin‐3‐gallate (EGCG) is the most abundant polyphenolic compounds of green tea, which has shown great therapeutic effectiveness in neurological disorders. However, it is still unknown whether and how EGCG affects METH seeking behaviour. Here, we show nanostructured EGCG/ascorbic acid nanoparticles (EGCG/AA NPs) dose‐dependently reduced METH self‐administration (SA) under fixed‐ratio 1 (FR1) and progressive ratio (PR) reinforcement schedules in mice and shifted METH dose–response curves downward. Furthermore, EGCG/AA NPs decreased drug‐ and cue‐induced METH seeking. In addition, we found that METH SA led to a decrease in inhibitory postsynaptic currents (IPSCs) and increase in the AMPAR/NMDAR ratio and excitation/inhibition (E/I) ratio in ex vivo midbrain slices from ventral tegmental area (VTA) dopamine neurons. EGCG/AA NPs enhanced Gamma‐aminobutyric acid (GABA)ergic inhibition and normalized the E/I ratio. EGCG restored the balance between excitation and inhibition in VTA dopamine neurons, which may contribute to the attenuation of METH SA. These findings indicate that EGCG is a promising pharmacotherapy for METH use disorder.